The angiokinase inhibitor nintedanib is used for treatment of metastatic NSCLC and EGFR inhibitor osimertinib is used for treatment of metastatic NSCLC with T790M-EGFR-mutation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.